CardiacAssist, Inc. Surpasses 1300 TandemHeart System Procedures

Circulatory assist device's high net flow rate supports a multitude of highly
complex procedures in life threatening situations

PITTSBURGH, June 19 /PRNewswire/ -- CardiacAssist, Inc., a Pittsburgh-
based medical device company that develops, manufacturers and markets cardiac
assist devices, has announced the completion of the 1300th worldwide procedure
utilizing the TandemHeart System. This is indicative of TandemHeart's
increasing acceptance and use by cardiologists and surgeons. The TandemHeart
System is unique in helping heart failure patients survive both heart attacks
and high risk procedures, while providing versatility to physicians in
choosing the time, place and type of treatments.
The TandemHeart System is now used in over 100 heart centers across the
U.S. Ten prestigious heart centers were recently active in helping
CardiacAssist, Inc. surpass the 1300th procedure for its TandemHeart System.
These ten heart centers include:
-- Brigham & Women's Hospital in Boston, MA
-- Cleveland Clinic in Cleveland, OH
-- Hospital of the University of Pennsylvania in Philadelphia, PA.
-- Lahey Clinic in Burlington, MA
-- Lenox Hill in New York City, NY
-- Mayo Clinic in Rochester, MN
-- Mt. Sinai in New York City, NY
-- Sacred Heart Medical Center in Spokane, WA
-- St. Luke's Hospital in Kansas City, MO
-- Texas Heart Institute in Houston, TX

In each situation the TandemHeart System was selected for its high net
flow rate of up to 5 lpm in the Cath Lab or up to 8 lpm in the OR as well as
its flexibility and rapid deployment potential. There are a variety of FDA
cleared devices that provide extracorporeal circulatory support, but all
others offer less than half the net flow and hemodynamic support of the
TandemHeart System.
The TandemHeart System is the only 5 lpm net flow, percutaneous
"extracorporeal circulatory support" device approved by the FDA for sale in
the U.S. Other devices including Impella 2.5 are labeled by the FDA to be used
for "partial circulatory support" with less than 2.5 lpm net flow.
The TandemHeart System is fully reimbursed by Medicare under existing DRG
codes. The device can be placed rapidly in the cath lab or operating room,
providing effective, reliable, temporary circulatory support for critically
ill patients.
Contact:
Pamela McDonald
Marketing Assistant
Ph: 412-963-7770 ext. 226
pmcdonald@cardiacassist.com

SOURCE CardiacAssist, Inc.

Pamela McDonald, Marketing Assistant of CardiacAssist, Inc., +1-412-963-7770
ext. 226, pmcdonald@cardiacassist.com